Division of Cancer, Department of Surgery and Cancer, Imperial College London, London, UK.
Oncogene. 2014 Feb 20;33(8):939-53. doi: 10.1038/onc.2013.80. Epub 2013 Mar 18.
The relevance of potentially reversible post-translational modifications required for controlling cellular processes in cancer is one of the most thriving arenas of cellular and molecular biology. Any alteration in the balanced equilibrium between kinases and phosphatases may result in development and progression of various diseases, including different types of cancer, though phosphatases are relatively under-studied. Loss of phosphatases such as PTEN (phosphatase and tensin homologue deleted on chromosome 10), a known tumour suppressor, across tumour types lends credence to the development of phosphatidylinositol 3-kinase inhibitors alongside the use of phosphatase expression as a biomarker, though phase 3 trial data are lacking. In this review, we give an updated report on phosphatase dysregulation linked to organ-specific malignancies.
对于控制癌症中细胞过程所需的潜在可逆转的翻译后修饰的相关性是细胞和分子生物学中最活跃的领域之一。激酶和磷酸酶之间平衡平衡的任何改变都可能导致各种疾病的发展和进展,包括不同类型的癌症,尽管磷酸酶的研究相对较少。在肿瘤类型中丢失诸如 PTEN(染色体 10 上缺失的磷酸酶和张力蛋白同源物)等磷酸酶,作为肿瘤抑制剂,为开发磷酸肌醇 3-激酶抑制剂以及使用磷酸酶表达作为生物标志物提供了依据,尽管缺乏 3 期临床试验数据。在这篇综述中,我们提供了与特定器官恶性肿瘤相关的磷酸酶失调的最新报告。